<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684771</url>
  </required_header>
  <id_info>
    <org_study_id>TEAM</org_study_id>
    <nct_id>NCT04684771</nct_id>
  </id_info>
  <brief_title>Tolerance, Efficacy, revAlidation, Myostim</brief_title>
  <official_title>Evaluation of Efficacy and Tolerance of a Food Supplement (MYOSTIM®) in Postoperative Revalidation of Patients After Reconstructive Surgery of Anterior Cruciate Ligament</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alternativa International S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Artialis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alternativa International S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of efficacy and tolerance of a food supplement (MYOSTIM®) versus a placebo in&#xD;
      postoperative revalidation of patients after reconstructive surgery of anterior cruciate&#xD;
      ligament.&#xD;
&#xD;
      The food supplement (MYOSTIM®) has been developped and is supplied as food bars and composed&#xD;
      of pomegranate, leucine, creatine, proteins and D vitamin. The aim of this exploratory study&#xD;
      is to assess the efficacy and tolerance of MYOSTIM® on muscle performance after ACL&#xD;
      reconstructive surgery and in postoperative revalidation phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, exploratory study, monocentric, with a group of control patient with placebo.&#xD;
Two parallel-groups receiving during 12 weeks either the MYOSTIM® or a PLACEBO in a double blinded manner.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Two parallel-groups either the MYOSTIM® or a PLACEBO in a double blinded manner.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the muscular strength recovery</measure>
    <time_frame>Change from Baseline at 14 weeks post ACL surgery</time_frame>
    <description>Evaluation by isokinetic test performed (extension/flexion of the quadriceps)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the muscular strength recovery</measure>
    <time_frame>Change from Baseline at 14 weeks post ACL surgery</time_frame>
    <description>Evaluation by isokinetic test performed (extension/flexion of the hamstrings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the muscular mass recovery</measure>
    <time_frame>Change from Baseline at 14 weeks post ACL surgery</time_frame>
    <description>Evaluation by Magnetic Resonance Imaging (MRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the muscular mass recovery</measure>
    <time_frame>Change from Baseline at 14 weeks post ACL surgery</time_frame>
    <description>Evaluation by impedancemetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on physical performance recovery</measure>
    <time_frame>Change from Baseline at 14 weeks post ACL surgery</time_frame>
    <description>Evaluation with one self-administrated knee evaluation questionnaire from the International Knee Documentation Committee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the effect of MYOSTIM® on blood biomarker</measure>
    <time_frame>Change from Baseline at 2 and14 weeks post ACL surgery</time_frame>
    <description>Evaluation of blood concentration of biomarker (Myostatin (muscular atrophy), Myeloperoxidase (chronic joint inflammation), Coll2-1 and Coll2-1NO2 (Cartilage inflammation and degradation), IL6 (muscular atrophy and inflammation), MMP3 and NT-CAF (cartilage and neuro-muscular junction), TNFa (inflammation))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the pain of the patient</measure>
    <time_frame>Change from Baseline at 2 and14 weeks post ACL surgery</time_frame>
    <description>Evaluation of pain of the patient by one visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the efficacy of MYOSTIM® on the global judgment of the patient</measure>
    <time_frame>Change from Baseline at 2 and14 weeks post ACL surgery</time_frame>
    <description>Evaluation of global judgment of the patient by one visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the tolerance of the patient with the MYOSTIM®</measure>
    <time_frame>At 14 weeks post ACL surgery</time_frame>
    <description>Evaluation according the number of Adverse Events (AE), remaining bars and satisfaction scale for the product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the compliance of the patient with the MYOSTIM®</measure>
    <time_frame>At 14 weeks post ACL surgery</time_frame>
    <description>Evaluation according the number of remaining bars</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the satisfaction of the patient with the MYOSTIM®</measure>
    <time_frame>At 14 weeks post ACL surgery</time_frame>
    <description>Evaluation according the satisfaction scale for the product</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Anterior Cruciate Ligament Rupture</condition>
  <arm_group>
    <arm_group_label>MYOSTIM®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO 2 bars/day during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MYOSTIM®</intervention_name>
    <description>Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.</description>
    <arm_group_label>MYOSTIM®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Bars with no active ingredient and the same flavor (chocolate and red fruits).</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between the age of 18 and 40&#xD;
&#xD;
          -  BMI (Body Mass Index) ≤ 27&#xD;
&#xD;
          -  Candidates for ACL reconstruction surgery of DIDT (Droit Interne et du Demi Tendineux)&#xD;
             type&#xD;
&#xD;
          -  Able to follow the instruction of the study, to go to the postoperative visits to the&#xD;
             investigator, to go to the isokinetic and to the MRI visits&#xD;
&#xD;
          -  Having signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Related to the pathology:&#xD;
&#xD;
          -  Patient who have undergone previous ACL reconstruction surgery on the same knee&#xD;
&#xD;
          -  Patient who have participated to a therapeutic clinical study 3 months before&#xD;
             inclusion&#xD;
&#xD;
          -  Patient who plan to follow a workout or a revalidation program after surgery different&#xD;
             from classical physiotherapy prescribed by the orthopedic surgeon&#xD;
&#xD;
          -  Contralateral limb suffered from trauma, surgery, fracture, tear, tendinopathy, sepsis&#xD;
             or immobilization for more than 3 weeks during the last 5 years&#xD;
&#xD;
        Related to treatment:&#xD;
&#xD;
          -  Patient who have eaten doping substances or food supplement building mass and muscle&#xD;
             strength during 3 months before inclusion excepted for creatine and beta-alanine for&#xD;
             which the washout period is of 6 month before inclusion&#xD;
&#xD;
          -  Patient who were treated with antibiotics in the month preceding the inclusion&#xD;
&#xD;
          -  Patient treated with pharmacologic agents like statins, immunosuppressors or&#xD;
             anti-malaria&#xD;
&#xD;
          -  Patient taking androgens (steroids…)&#xD;
&#xD;
          -  Patient under treatments which may interfere with the neuromuscular system&#xD;
&#xD;
          -  Patient who were treated with analgesic or non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDS) 24 hours before inclusion visit&#xD;
&#xD;
        Related to associated diseases:&#xD;
&#xD;
          -  Patient with associated uncontrolled severe disease: severe liver or kidney disease,&#xD;
             severe and uncontrolled cardiovascular disease, HIV, B or C hepatitis, tumor&#xD;
&#xD;
          -  Patient with thromboembolism disorders&#xD;
&#xD;
          -  Patient with inflammatory bowel disease&#xD;
&#xD;
          -  Anorexic patient&#xD;
&#xD;
          -  Diabetic patient&#xD;
&#xD;
          -  Patient with traumatic, neurologic or rheumatic history of the lower limbs&#xD;
&#xD;
        Related to patient:&#xD;
&#xD;
          -  Allergy or contraindication to soy, milk, gluten, nuts or wheat&#xD;
&#xD;
          -  Forecasting a high protein diet during the study&#xD;
&#xD;
          -  Under guardianship or judicial protection&#xD;
&#xD;
        Related to MRI counter-indication:&#xD;
&#xD;
          -  Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a&#xD;
             neurostimulator, cochlear implant, a stent from less than 3 weeks, an insulin pump&#xD;
&#xD;
          -  Patient with a ferromagnetic splinter in the body, or having wire sutures&#xD;
&#xD;
          -  Serious mobility problem (Parkinson, tremors)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
        Related to impedancemeter test:&#xD;
&#xD;
        • Patient with a metal plate at the right ankle&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Bois de l'Abbaye et de Hesbaye</name>
      <address>
        <city>Seraing</city>
        <state>Liège</state>
        <zip>4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food supplement</keyword>
  <keyword>revalidation after surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

